Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2

Sponsor Class

OTHER 928INDUSTRY 391NIH 107NETWORK 49OTHER_GOV 9UNKNOWN 2FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Paclitaxel 20Capecitabine 18S 1 (combination) 17Cisplatin 15Oxaliplatin 11Radiotherapy, Intensity-Modulated 9apatinib 8Epirubicin 8Docetaxel 8Carboplatin 8Radiotherapy 7Irinotecan 7titanium silicide 6sintilimab 6pyrotinib 6nimotuzumab 6anlotinib 6Drug Therapy 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6nedaplatin 5camrelizumab 5Temozolomide 5Etoposide 5Bevacizumab 5nabiximols 4Vinorelbine 4Trastuzumab 4Radiation Dose Hypofractionation 4Radiation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
UNKNOWN × Rituximab × Clear all
NCT04994626 2021-08-06

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

ChineseAMS

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Recurrence

NCT04425824 2020-06-16

Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma

ChineseAMS

Phase 2 Unknown
20 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡